# Official Journal C 211/2012

| | ISSN 1977-091X
  doi:10.3000/1977091X.C_2012.211.eng |
| --- | --- |
| Official Journal
  of the European Union | C 211 |
| | |
| English edition | Information and Notices | Volume 5518 July 2012 |

ISSN 1977-091X

doi:10.3000/1977091X.C_2012.211.eng

Official Journal

of the European Union

C 211

English edition

Information and Notices

Volume 5518 July 2012

---

| Notice No | Contents | page |
| --- | --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2012/C 211/01 | Non-opposition to a notified concentration (Case COMP/M.6578 — Tyco Flow Control International/Pentair) (
  1
  ) | 1 |

Notice No

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2012/C 211/01

Non-opposition to a notified concentration (Case COMP/M.6578 — Tyco Flow Control International/Pentair) (
  1
  )

1

1

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | Council |
| 2012/C 211/02 | Council conclusions of 22 June 2012 on the impact of antimicrobial resistance in the human health sector and in the veterinary sector — a One Health perspective | 2 |
| | European Commission |
| 2012/C 211/03 | Euro exchange rates | 6 |
| | NOTICES FROM MEMBER STATES |
| 2012/C 211/04 | List of Member States Licencing Offices as provided for in Article 10(7) of Commission Implementing Regulation (EU) No 498/2012 | 7 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

2012/C 211/02

Council conclusions of 22 June 2012 on the impact of antimicrobial resistance in the human health sector and in the veterinary sector — a One Health perspective

2

European Commission

2012/C 211/03

Euro exchange rates

6

NOTICES FROM MEMBER STATES

2012/C 211/04

List of Member States Licencing Offices as provided for in Article 10(7) of Commission Implementing Regulation (EU) No 498/2012

7

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 18.7.2012 | EN | Official Journal of the European Union | C 211/1 |
| --- | --- | --- | --- |

18.7.2012

EN

Official Journal of the European Union

C 211/1

---

Non-opposition to a notified concentration

(Case COMP/M.6578 — Tyco Flow Control International/Pentair)

(Text with EEA relevance)

2012/C 211/01

On 11 July 2012, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32012M6578. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32012M6578. EUR-Lex is the on-line access to the European law.

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

| 18.7.2012 | EN | Official Journal of the European Union | C 211/2 |
| --- | --- | --- | --- |

18.7.2012

EN

Official Journal of the European Union

C 211/2

---

Council conclusions of 22 June 2012 on the impact of antimicrobial resistance in the human health sector and in the veterinary sector — a ‘One Health’ perspective

2012/C 211/02

THE COUNCIL OF THE EUROPEAN UNION

| 1. | RECALLS the Council conclusions of 10 June 2008 on antimicrobial resistance (AMR) (1). |
| --- | --- |

1.

RECALLS the Council conclusions of 10 June 2008 on antimicrobial resistance (AMR) (1).

| 2. | RECALLS the Council conclusions of 23 November 2009 on innovative incentives for effective antibiotics (2). |
| --- | --- |

2.

RECALLS the Council conclusions of 23 November 2009 on innovative incentives for effective antibiotics (2).

| 3. | RECALLS the Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (3), including the reports of December 2005 and April 2010 from the Commission to the Council on its implementation (4). |
| --- | --- |

3.

RECALLS the Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (3), including the reports of December 2005 and April 2010 from the Commission to the Council on its implementation (4).

| 4. | RECALLS the Council Recommendation of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections (5). |
| --- | --- |

4.

RECALLS the Council Recommendation of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections (5).

| 5. | ACKNOWLEDGES the Scientific Opinion of October 2009 of the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA), the European Medicines Agency (EMA) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) on antimicrobial resistance focused on zoonotic infections (6). |
| --- | --- |

5.

ACKNOWLEDGES the Scientific Opinion of October 2009 of the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA), the European Medicines Agency (EMA) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) on antimicrobial resistance focused on zoonotic infections (6).

| 6. | ACKNOWLEDGES the European Parliament Resolution of 5 May 2010 on evaluation and assessment of Animal Welfare Action Plan 2006-2010 (7). |
| --- | --- |

6.

ACKNOWLEDGES the European Parliament Resolution of 5 May 2010 on evaluation and assessment of Animal Welfare Action Plan 2006-2010 (7).

| 7. | RECALLS the European Parliament Resolutions of 12 May 2011 on antibiotic resistance (8) and of 27 October 2011 on the public health threat of antimicrobial resistance (9). |
| --- | --- |

7.

RECALLS the European Parliament Resolutions of 12 May 2011 on antibiotic resistance (8) and of 27 October 2011 on the public health threat of antimicrobial resistance (9).

| 8. | WELCOMES the European Commission Communication of 15 November 2011 on an action plan against the rising threats from Antimicrobial Resistance (10). |
| --- | --- |

8.

WELCOMES the European Commission Communication of 15 November 2011 on an action plan against the rising threats from Antimicrobial Resistance (10).

| 9. | RECALLS the Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition prohibiting the use of antibiotic growth promoters (11). |
| --- | --- |

9.

RECALLS the Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition prohibiting the use of antibiotic growth promoters (11).

| 10. | STRESSES that AMR is a growing European and global health problem in both humans and animals, leading to limited or poor options for treatment whilst diminishing the quality of life and to important economic consequences in terms of augmenting healthcare costs and productivity losses. |
| --- | --- |

10.

STRESSES that AMR is a growing European and global health problem in both humans and animals, leading to limited or poor options for treatment whilst diminishing the quality of life and to important economic consequences in terms of augmenting healthcare costs and productivity losses.

| 11. | RECOGNISES that the development of AMR is accelerated by excessive and inappropriate use of antimicrobial agents which, together with poor hygiene or poor infection control practices, creates favourable conditions for the development, spread and persistence of resistant micro-organisms in both humans and animals. |
| --- | --- |

11.

RECOGNISES that the development of AMR is accelerated by excessive and inappropriate use of antimicrobial agents which, together with poor hygiene or poor infection control practices, creates favourable conditions for the development, spread and persistence of resistant micro-organisms in both humans and animals.

| 12. | RECOGNISES that there are varying situations and different approaches in prescription, use and distribution of antimicrobials in the Member States, including types of antimicrobials used, in human medicine and in veterinary medicine. |
| --- | --- |

12.

RECOGNISES that there are varying situations and different approaches in prescription, use and distribution of antimicrobials in the Member States, including types of antimicrobials used, in human medicine and in veterinary medicine.

| 13. | UNDERLINES the need for an active holistic risk based approach based on a ‘One Health’ perspective with the purpose of reducing the use of antimicrobials as much as possible and to maximise coordinated efforts between the human health sector and the veterinary sector in the fight against AMR. |
| --- | --- |

13.

UNDERLINES the need for an active holistic risk based approach based on a ‘One Health’ perspective with the purpose of reducing the use of antimicrobials as much as possible and to maximise coordinated efforts between the human health sector and the veterinary sector in the fight against AMR.

| 14. | STRESSES that microbiological diagnosis together with standardised susceptibility testing create the basis for a correct choice of antimicrobial treatment and de-escalation of the initial empirical treatment, thus allowing antimicrobials to be used in the most appropriate way with the objective to limiting the use of antimicrobials in general and especially of critically important antimicrobials (CIAs). |
| --- | --- |

14.

STRESSES that microbiological diagnosis together with standardised susceptibility testing create the basis for a correct choice of antimicrobial treatment and de-escalation of the initial empirical treatment, thus allowing antimicrobials to be used in the most appropriate way with the objective to limiting the use of antimicrobials in general and especially of critically important antimicrobials (CIAs).

| 15. | ACKNOWLEDGES the definitions of CIAs for humans and animals by the World Health Organisation (WHO) and the World Organisation for Animal Health (OIE), respectively, as the basis for European efforts. |
| --- | --- |

15.

ACKNOWLEDGES the definitions of CIAs for humans and animals by the World Health Organisation (WHO) and the World Organisation for Animal Health (OIE), respectively, as the basis for European efforts.

| 16. | STRESSES the need to target the use of CIAs to specific cases in which the use is considered appropriate. |
| --- | --- |

16.

STRESSES the need to target the use of CIAs to specific cases in which the use is considered appropriate.

| 17. | STRESSES the need to be restrictive in both the human and veterinary use of CIAs and newly developed antimicrobials, eventually with the aim in the future to reserve CIAs as much as possible for human use. |
| --- | --- |

17.

STRESSES the need to be restrictive in both the human and veterinary use of CIAs and newly developed antimicrobials, eventually with the aim in the future to reserve CIAs as much as possible for human use.

| 18. | STRESSES the need for all Member States to require that, as a minimum, oral, inhaled and parenteral antimicrobial agents are only available through prescription or in clearly defined circumstances, under the supervision of a regulated health care professional. |
| --- | --- |

18.

STRESSES the need for all Member States to require that, as a minimum, oral, inhaled and parenteral antimicrobial agents are only available through prescription or in clearly defined circumstances, under the supervision of a regulated health care professional.

| 19. | RECOGNISES that some practises in human and in animal healthcare including the possible incentives deriving from the prescription and subsequent sale of antimicrobial agents may lead to inappropriate use and overuse of antimicrobial agents. |
| --- | --- |

19.

RECOGNISES that some practises in human and in animal healthcare including the possible incentives deriving from the prescription and subsequent sale of antimicrobial agents may lead to inappropriate use and overuse of antimicrobial agents.

| 20. | STRESSES the importance of effective surveillance systems in both the human health sector and the veterinary sector based on existing monitoring systems under the auspices of EFSA, the ECDC European Surveillance of Antimicrobial Consumption Network (ESAC-net), the ECDC European Antimicrobial Resistance Surveillance Network (EARS-net), and the EMA European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) to allow collection of comparable and timely data on AMR and on the use of antimicrobial agents. |
| --- | --- |

20.

STRESSES the importance of effective surveillance systems in both the human health sector and the veterinary sector based on existing monitoring systems under the auspices of EFSA, the ECDC European Surveillance of Antimicrobial Consumption Network (ESAC-net), the ECDC European Antimicrobial Resistance Surveillance Network (EARS-net), and the EMA European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) to allow collection of comparable and timely data on AMR and on the use of antimicrobial agents.

| 21. | RECOGNISES the importance of EU support through existing EU financial instruments such as the Health Programme and the EU Framework Programme for Research and Innovation including the Innovative Medicine Initiative (IMI) to improve research and development on AMR and strengthen prevention and control against AMR and the need to continue these activities and implementing the results. |
| --- | --- |

21.

RECOGNISES the importance of EU support through existing EU financial instruments such as the Health Programme and the EU Framework Programme for Research and Innovation including the Innovative Medicine Initiative (IMI) to improve research and development on AMR and strengthen prevention and control against AMR and the need to continue these activities and implementing the results.

| 22. | STRESSES the importance of enhancing the coordination of Member States research activities on countering AMR in the EU (12). |
| --- | --- |

22.

STRESSES the importance of enhancing the coordination of Member States research activities on countering AMR in the EU (12).

| 23. | STRESSES the need to actively raise awareness in the general public, and in the human health sector and veterinary sector about the risks of AMR due to excessive and inappropriate use of antimicrobial agents and the consequences of AMR for the individual and society in general and, RECOGNISES the importance of the European Antibiotic Awareness Day as a platform for national awareness campaigns. |
| --- | --- |

23.

STRESSES the need to actively raise awareness in the general public, and in the human health sector and veterinary sector about the risks of AMR due to excessive and inappropriate use of antimicrobial agents and the consequences of AMR for the individual and society in general and, RECOGNISES the importance of the European Antibiotic Awareness Day as a platform for national awareness campaigns.

| 24. | STRESSES the importance of continuous training and education of human health and veterinary professionals in the diagnosis, treatment and prevention of infectious diseases and in the appropriate use of antimicrobials and where relevant, continuous training and education in prevention of infectious diseases and in the appropriate use of antimicrobials shall also involve livestock keepers. |
| --- | --- |

24.

STRESSES the importance of continuous training and education of human health and veterinary professionals in the diagnosis, treatment and prevention of infectious diseases and in the appropriate use of antimicrobials and where relevant, continuous training and education in prevention of infectious diseases and in the appropriate use of antimicrobials shall also involve livestock keepers.

| 25. | RECOGNISES that health care acquired infections are an important factor in the spread of antimicrobial resistance and in an increased use of antibiotics. |
| --- | --- |

25.

RECOGNISES that health care acquired infections are an important factor in the spread of antimicrobial resistance and in an increased use of antibiotics.

| 26. | STRESSES the importance of effective preventive and hygiene measures, especially hand hygiene and biosecurity measures to prevent and control infections and their spread in both the human health sector and in the veterinary sector. |
| --- | --- |

26.

STRESSES the importance of effective preventive and hygiene measures, especially hand hygiene and biosecurity measures to prevent and control infections and their spread in both the human health sector and in the veterinary sector.

| 27. | HIGHLIGHTS the importance of international cooperation on AMR, including the work carried out by the World Health Organisation (WHO), the World Organisation for Animal Health (OIE), Codex Alimentarius and the Transatlantic Task Force on Antimicrobial Resistance (TATFAR). |
| --- | --- |

27.

HIGHLIGHTS the importance of international cooperation on AMR, including the work carried out by the World Health Organisation (WHO), the World Organisation for Animal Health (OIE), Codex Alimentarius and the Transatlantic Task Force on Antimicrobial Resistance (TATFAR).

| 28. | WELCOMES the Conference on AMR in Copenhagen on 14-15 March 2012, which provided valuable contributions to the further work to counter AMR through actions against overuse of antimicrobials in humans and animals with a particular focus on CIAs and strengthened surveillance. |
| --- | --- |

28.

WELCOMES the Conference on AMR in Copenhagen on 14-15 March 2012, which provided valuable contributions to the further work to counter AMR through actions against overuse of antimicrobials in humans and animals with a particular focus on CIAs and strengthened surveillance.

| 29. | CALLS UPON THE MEMBER STATES TO:






  1) | develop and implement national strategies or action plans for countering AMR which include the following elements:






  a) | development and implementation of national guidelines on the treatment of humans and animals with antimicrobial agents ensuring a more prudent use and thus a reduced risk of AMR; |
| --- | --- | --- | --- |

29.

CALLS UPON THE MEMBER STATES TO:

1)

develop and implement national strategies or action plans for countering AMR which include the following elements:

a)

development and implementation of national guidelines on the treatment of humans and animals with antimicrobial agents ensuring a more prudent use and thus a reduced risk of AMR;

| b) | Clinical sampling and the use of diagnostic on-site tests and susceptibility testing in order to secure that antimicrobial treatments are based on microbiological diagnosis and susceptibility and ensure sufficient microbiological capacity specifically adapted to both human and veterinary use; |
| --- | --- |

b)

Clinical sampling and the use of diagnostic on-site tests and susceptibility testing in order to secure that antimicrobial treatments are based on microbiological diagnosis and susceptibility and ensure sufficient microbiological capacity specifically adapted to both human and veterinary use;

| c) | development and implementation of communication guidelines and programmes for education and training of professionals on the appropriate use of antimicrobial agents and methods to reduce the transmission of pathogens, including infection control and hygiene measures in both the human health sector and the veterinary sector; |
| --- | --- |

c)

development and implementation of communication guidelines and programmes for education and training of professionals on the appropriate use of antimicrobial agents and methods to reduce the transmission of pathogens, including infection control and hygiene measures in both the human health sector and the veterinary sector;

| d) | enforcement of national legislation preventing all illegal sales of antimicrobials including illegal sales over the internet, in both the human health sector and the veterinary sector; |
| --- | --- |

d)

enforcement of national legislation preventing all illegal sales of antimicrobials including illegal sales over the internet, in both the human health sector and the veterinary sector;

| e) | limit the use of CIAs to cases where microbiological diagnosis and susceptibility testing has determined that no other type of antimicrobials will be effective. In acute cases in the treatment of infections in humans and animals, CIAs can be used initially when necessary, but must be re-evaluated and if possible de-escalated depending on test results; |
| --- | --- |

e)

limit the use of CIAs to cases where microbiological diagnosis and susceptibility testing has determined that no other type of antimicrobials will be effective. In acute cases in the treatment of infections in humans and animals, CIAs can be used initially when necessary, but must be re-evaluated and if possible de-escalated depending on test results;

| f) | limit prophylactic use of antimicrobials to cases with defined clinical needs; |
| --- | --- |

f)

limit prophylactic use of antimicrobials to cases with defined clinical needs;

| g) | limit prescription and use of antimicrobials for herd treatment of animals to cases where a veterinarian has assessed that there is a clear clinical and, where appropriate, epidemiological justification to treat all animals; |
| --- | --- |

g)

limit prescription and use of antimicrobials for herd treatment of animals to cases where a veterinarian has assessed that there is a clear clinical and, where appropriate, epidemiological justification to treat all animals;

| h) | encourage incentives for the animal production and marketing systems that serves the continuous improvement of animal health, including the prevention of diseases, enhancement of hygiene measures and as a result reduce the need for antimicrobials; |
| --- | --- |

h)

encourage incentives for the animal production and marketing systems that serves the continuous improvement of animal health, including the prevention of diseases, enhancement of hygiene measures and as a result reduce the need for antimicrobials;

| i) | ensure effective surveillance systems, including both the human health sector and the veterinary sector with the aim of collecting timely data that are comparable between sectors and Member States on AMR and on the use of antimicrobial agents; |
| --- | --- |

i)

ensure effective surveillance systems, including both the human health sector and the veterinary sector with the aim of collecting timely data that are comparable between sectors and Member States on AMR and on the use of antimicrobial agents;

| j) | transmission to surveillance systems of data on the prescription and/or sales of all antimicrobial agents for use in humans; |
| --- | --- |

j)

transmission to surveillance systems of data on the prescription and/or sales of all antimicrobial agents for use in humans;

| k) | collect data on sale and use of antimicrobials in animals; |
| --- | --- |

k)

collect data on sale and use of antimicrobials in animals;

| l) | set up an intersectoral coordination mechanism at national level involving relevant authorities and sectors to monitor the implementation of the national strategies or action plans on antimicrobial use and resistance. |
| --- | --- |

l)

set up an intersectoral coordination mechanism at national level involving relevant authorities and sectors to monitor the implementation of the national strategies or action plans on antimicrobial use and resistance.

| 30. | CALLS UPON THE MEMBER STATES AND THE COMMISSION TO:






  1) | ensure continued advancement and strengthening of intersectoral cooperation, nationally and internationally, including on the advancement of prudent use of antimicrobial agents. Where appropriate identify options and models to strengthen incentives to conduct research and development of new effective antimicrobials or alternatives and their controlled use; |
| --- | --- | --- |

30.

CALLS UPON THE MEMBER STATES AND THE COMMISSION TO:

1)

ensure continued advancement and strengthening of intersectoral cooperation, nationally and internationally, including on the advancement of prudent use of antimicrobial agents. Where appropriate identify options and models to strengthen incentives to conduct research and development of new effective antimicrobials or alternatives and their controlled use;

| 2) | continue the efforts to raise public awareness about the risks of AMR due to excessive use of antimicrobial agents, including through continued support for the European Antibiotics Awareness Day; |
| --- | --- |

2)

continue the efforts to raise public awareness about the risks of AMR due to excessive use of antimicrobial agents, including through continued support for the European Antibiotics Awareness Day;

| 3) | develop a classification of antimicrobials including a specific list that are essential to treat infections caused by multiresistant organisms for which other antimicrobials have become ineffective and to promote and carry out education and guidance of health and veterinary professionals alike on limiting the use of these antimicrobials for humans and especially for animals; |
| --- | --- |

3)

develop a classification of antimicrobials including a specific list that are essential to treat infections caused by multiresistant organisms for which other antimicrobials have become ineffective and to promote and carry out education and guidance of health and veterinary professionals alike on limiting the use of these antimicrobials for humans and especially for animals;

| 4) | invite WHO and OIE to collaborate on the update of the respective lists of CIAs for the human and veterinary sector; |
| --- | --- |

4)

invite WHO and OIE to collaborate on the update of the respective lists of CIAs for the human and veterinary sector;

| 5) | cooperate on the early detection of pathogenic antimicrobial resistant bacteria in humans, in animals and in food in order to continuously monitor the development of AMR; |
| --- | --- |

5)

cooperate on the early detection of pathogenic antimicrobial resistant bacteria in humans, in animals and in food in order to continuously monitor the development of AMR;

| 6) | use the existing early warning systems for the swift detection of new mechanisms of resistance; |
| --- | --- |

6)

use the existing early warning systems for the swift detection of new mechanisms of resistance;

| 7) | Examine the conditions for prescription and sale of antimicrobials in order to ascertain whether practices in human and animal healthcare may lead to over-prescription, overuse or misuse of antimicrobials; |
| --- | --- |

7)

Examine the conditions for prescription and sale of antimicrobials in order to ascertain whether practices in human and animal healthcare may lead to over-prescription, overuse or misuse of antimicrobials;

| 8) | work actively to promote international initiatives to limit the use of antimicrobials which would include international requirements on prescription for antimicrobials, international requirements on surveillance and reporting of antimicrobial use and resistance and a global ban on antimicrobial growth promoters in animals; |
| --- | --- |

8)

work actively to promote international initiatives to limit the use of antimicrobials which would include international requirements on prescription for antimicrobials, international requirements on surveillance and reporting of antimicrobial use and resistance and a global ban on antimicrobial growth promoters in animals;

| 9) | work actively to promote adoption of rules at international level, including through WHO resolutions and OIE and Codex Alimentarius standards, for surveillance and reporting of antimicrobial use and resistance; |
| --- | --- |

9)

work actively to promote adoption of rules at international level, including through WHO resolutions and OIE and Codex Alimentarius standards, for surveillance and reporting of antimicrobial use and resistance;

| 10) | reinforce and coordinate research and innovation efforts to combat AMR and to maintain the efficacy and availability of existing antimicrobials, including through public-private collaboration. |
| --- | --- |

10)

reinforce and coordinate research and innovation efforts to combat AMR and to maintain the efficacy and availability of existing antimicrobials, including through public-private collaboration.

| 31. | CALLS UPON THE COMMISSION TO:






  1) | follow up on its Communication of 15 November 2011 through concrete initiatives to implement the 12 actions indicated in the Communication, and to present a timeline for the implementation of the initiatives and for the reporting on the implementation to the Council; |
| --- | --- | --- |

31.

CALLS UPON THE COMMISSION TO:

1)

follow up on its Communication of 15 November 2011 through concrete initiatives to implement the 12 actions indicated in the Communication, and to present a timeline for the implementation of the initiatives and for the reporting on the implementation to the Council;

| 2) | expand the existing food and veterinary working group on AMR to fully involve the human health sector to support the implementation of a comprehensive approach against AMR at EU and national level taking into account the ‘One Health’ perspective of the initiatives; |
| --- | --- |

2)

expand the existing food and veterinary working group on AMR to fully involve the human health sector to support the implementation of a comprehensive approach against AMR at EU and national level taking into account the ‘One Health’ perspective of the initiatives;

| 3) | expedite the review of Directives 90/167/EEC laying down the conditions governing the preparation, placing on the market and use of medicated feedingstuffs in the Community (13), and 2001/82/EC on the Community code relating to veterinary medicinal products (14), taking AMR better into account, including considering that prescription of antibiotic veterinary medical products may only be carried out by a veterinarian; |
| --- | --- |

3)

expedite the review of Directives 90/167/EEC laying down the conditions governing the preparation, placing on the market and use of medicated feedingstuffs in the Community (13), and 2001/82/EC on the Community code relating to veterinary medicinal products (14), taking AMR better into account, including considering that prescription of antibiotic veterinary medical products may only be carried out by a veterinarian;

| 4) | collaborate closely with the ECDC, EFSA and EMA in strengthening the assessment and evaluation of the occurrence of AMR in humans, in animals and in food in the EU; |
| --- | --- |

4)

collaborate closely with the ECDC, EFSA and EMA in strengthening the assessment and evaluation of the occurrence of AMR in humans, in animals and in food in the EU;

| 5) | ensure effective mechanisms to process data from the Member States’ surveillance systems on AMR in humans, animals and food and on the use of antimicrobial agents in humans and animals in order to ensure timely and comparable data in the EU; |
| --- | --- |

5)

ensure effective mechanisms to process data from the Member States’ surveillance systems on AMR in humans, animals and food and on the use of antimicrobial agents in humans and animals in order to ensure timely and comparable data in the EU;

| 6) | initiate baseline surveys on AMR in both humans, animals and food at appropriate intervals; |
| --- | --- |

6)

initiate baseline surveys on AMR in both humans, animals and food at appropriate intervals;

| 7) | collaborate with other countries and international organisations to scale up visibility and raise global awareness of the issue of AMR and develop and strengthen multilateral and bilateral commitments for the prevention and control of AMR in all sectors; |
| --- | --- |

7)

collaborate with other countries and international organisations to scale up visibility and raise global awareness of the issue of AMR and develop and strengthen multilateral and bilateral commitments for the prevention and control of AMR in all sectors;

| 8) | follow up on the Council conclusions in connection with the evaluation of its Communication of 15 November 2011 by including national follow-up reports on the implementation and actions taken at national level. |
| --- | --- |

8)

follow up on the Council conclusions in connection with the evaluation of its Communication of 15 November 2011 by including national follow-up reports on the implementation and actions taken at national level.

---

(1)  9637/08.

(2)  OJ C 302, 12.12.2009, p. 10.

(3)  OJ L 34, 5.2.2002, p. 13.

(4)  5427/06 (COM(2005) 684 final) and 8493/10 (COM(2010) 141 final).

(5)  OJ C 151, 3.7.2009, p. 1.

(6)  EFSA Journal 2009; 7(11):1372, http://ec.europa.eu/health/scientific_committees/emerging/opinions/scenihr_o_026.pdf EMEA/CVMP/447259/2009

(7)  P7_TA(2010)0130.

(8)  P7_TA(2011)0238.

(9)  P7_TA(2011)0473.

(10)  16939/11 (COM(2011) 748).

(11)  OJ L 268, 18.10.2003, p. 29.

(12)  16314/11 (C(2011)7660) Commission Recommendation of 27.10.2011 on the research joint programming initiative ‘The Microbial Challenge — An Emerging Threat to Human Health’.

(13)  OJ L 92, 7.4.1990, p. 42.

(14)  OJ L 136, 30.4.2004, p. 58.

---

European Commission

| 18.7.2012 | EN | Official Journal of the European Union | C 211/6 |
| --- | --- | --- | --- |

18.7.2012

EN

Official Journal of the European Union

C 211/6

---

Euro exchange rates (1)

17 July 2012

2012/C 211/03

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2281 |
| JPY | Japanese yen | 97,14 |
| DKK | Danish krone | 7,4421 |
| GBP | Pound sterling | 0,78615 |
| SEK | Swedish krona | 8,6046 |
| CHF | Swiss franc | 1,2010 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 7,4750 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 25,340 |
| HUF | Hungarian forint | 286,81 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6962 |
| PLN | Polish zloty | 4,1705 |
| RON | Romanian leu | 4,5673 |
| TRY | Turkish lira | 2,2253 |
| AUD | Australian dollar | 1,1941 |
| CAD | Canadian dollar | 1,2463 |
| HKD | Hong Kong dollar | 9,5253 |
| NZD | New Zealand dollar | 1,5394 |
| SGD | Singapore dollar | 1,5495 |
| KRW | South Korean won | 1 404,93 |
| ZAR | South African rand | 10,0543 |
| CNY | Chinese yuan renminbi | 7,8282 |
| HRK | Croatian kuna | 7,4820 |
| IDR | Indonesian rupiah | 11 605,97 |
| MYR | Malaysian ringgit | 3,8912 |
| PHP | Philippine peso | 51,295 |
| RUB | Russian rouble | 39,8050 |
| THB | Thai baht | 38,783 |
| BRL | Brazilian real | 2,4966 |
| MXN | Mexican peso | 16,1864 |
| INR | Indian rupee | 67,6010 |

Currency

Exchange rate

USD

US dollar

1,2281

JPY

Japanese yen

97,14

DKK

Danish krone

7,4421

GBP

Pound sterling

0,78615

SEK

Swedish krona

8,6046

CHF

Swiss franc

1,2010

ISK

Iceland króna

NOK

Norwegian krone

7,4750

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

25,340

HUF

Hungarian forint

286,81

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6962

PLN

Polish zloty

4,1705

RON

Romanian leu

4,5673

TRY

Turkish lira

2,2253

AUD

Australian dollar

1,1941

CAD

Canadian dollar

1,2463

HKD

Hong Kong dollar

9,5253

NZD

New Zealand dollar

1,5394

SGD

Singapore dollar

1,5495

KRW

South Korean won

1 404,93

ZAR

South African rand

10,0543

CNY

Chinese yuan renminbi

7,8282

HRK

Croatian kuna

7,4820

IDR

Indonesian rupiah

11 605,97

MYR

Malaysian ringgit

3,8912

PHP

Philippine peso

51,295

RUB

Russian rouble

39,8050

THB

Thai baht

38,783

BRL

Brazilian real

2,4966

MXN

Mexican peso

16,1864

INR

Indian rupee

67,6010

---

(1)  Source: reference exchange rate published by the ECB.

---

NOTICES FROM MEMBER STATES

| 18.7.2012 | EN | Official Journal of the European Union | C 211/7 |
| --- | --- | --- | --- |

18.7.2012

EN

Official Journal of the European Union

C 211/7

---

List of Member States Licencing Offices as provided for in Article 10(7) of Commission Implementing Regulation (EU) No 498/2012 (1)

2012/C 211/04

1.   Belgium

| FOD Economie, KMO, Middenstand en Energie |
| --- |
| Algemene Directie Economisch Potentieel |
| Dienst Vergunningen |
| Vooruitgangstraat 50 |
| 1210 Brussel |
| BELGIË |
| Tel. +32 22776713 |
| Fax +32 22775063 |

FOD Economie, KMO, Middenstand en Energie

Algemene Directie Economisch Potentieel

Dienst Vergunningen

Vooruitgangstraat 50

1210 Brussel

BELGIË

Tel. +32 22776713

Fax +32 22775063

| SPF Économie, PME, Classes moyennes et Énergie |
| --- |
| Direction générale Potentiel économique |
| Service Licences |
| Rue du Progrès 50 |
| 1210 Bruxelles |
| BELGIQUE |
| Tel. +32 22776713 |
| Fax +32 22775063 |

SPF Économie, PME, Classes moyennes et Énergie

Direction générale Potentiel économique

Service Licences

Rue du Progrès 50

1210 Bruxelles

BELGIQUE

Tel. +32 22776713

Fax +32 22775063

2.   Bulgaria

| Министерство на икономиката, енергетиката и туризма |
| --- |
| Дирекция „Регистриране, лицензиране и контрол“ |
| ул. „Славянска“ No 8 |
| 1052 София/Sofia |
| БЪЛГАРИЯ/BULGARIA |
| Тel. +359 29407008 / 29407673 / 29407800 |
| Fax +359 29815041 / 29804710 / 29883654 |

Министерство на икономиката, енергетиката и туризма

Дирекция „Регистриране, лицензиране и контрол“

ул. „Славянска“ No 8

1052 София/Sofia

БЪЛГАРИЯ/BULGARIA

Тel. +359 29407008 / 29407673 / 29407800

Fax +359 29815041 / 29804710 / 29883654

| Ministry of Economy, Energy and Tourism |
| --- |
| Slavyanska 8 |
| 1052 Sofia |
| BULGARIA |
| Tel. +359 29407008 / 29407673 / 29407800 |
| Fax +359 29815041 / 29804710 / 29883654 |

Ministry of Economy, Energy and Tourism

Slavyanska 8

1052 Sofia

BULGARIA

Tel. +359 29407008 / 29407673 / 29407800

Fax +359 29815041 / 29804710 / 29883654

3.   Czech Republic

| Ministerstvo průmyslu a obchodu |
| --- |
| Licenční správa |
| Na Františku 32 |
| 110 15 Praha 1 |
| ČESKÁ REPUBLIKA |
| Tel. +420 224907111 |
| Fax +420 224212133 |

Ministerstvo průmyslu a obchodu

Licenční správa

Na Františku 32

110 15 Praha 1

ČESKÁ REPUBLIKA

Tel. +420 224907111

Fax +420 224212133

4.   Denmark

| Erhvervs- og Vækstministeriet |
| --- |
| Erhvervsstyrelsen |
| Langelinje Allé 17 |
| 2100 København |
| DANMARK |
| Tel. +45 35466030 |
| Fax +45 35466029 |

Erhvervs- og Vækstministeriet

Erhvervsstyrelsen

Langelinje Allé 17

2100 København

DANMARK

Tel. +45 35466030

Fax +45 35466029

5.   Germany

| Bundesamt für Wirtschaft und Ausfuhrkontrolle (BAFA) |
| --- |
| Frankfurter Str. 29-35 |
| 65760 Eschborn |
| DEUTSCHLAND |
| Tel. +49 61969080 |
| Fax +49 6196908800 |

Bundesamt für Wirtschaft und Ausfuhrkontrolle (BAFA)

Frankfurter Str. 29-35

65760 Eschborn

DEUTSCHLAND

Tel. +49 61969080

Fax +49 6196908800

6.   Estonia

| Majandus- ja Kommunikatsiooniministeerium |
| --- |
| Harju 11 |
| 15072 Tallinn |
| EESTI/ESTONIA |
| Tel. +372 6256400 |
| Fax +372 6313660 |

Majandus- ja Kommunikatsiooniministeerium

Harju 11

15072 Tallinn

EESTI/ESTONIA

Tel. +372 6256400

Fax +372 6313660

7.   Ireland

| Department of Enterprise, Trade and Employment |
| --- |
| Internal Market |
| Kildare Street |
| Dublin 2 |
| IRELAND |
| Tel. +353 16312121 |
| Fax +353 16312826 |

Department of Enterprise, Trade and Employment

Internal Market

Kildare Street

Dublin 2

IRELAND

Tel. +353 16312121

Fax +353 16312826

8.   Greece

| Υπουργείο Ανάπτυξης, Ανταγωνιστικότητας & Ναυτιλίας |
| --- |
| Γενική Διεύθυνση Διεθνούς Οικονομικής Πολιτικής |
| Διεύθυνση Καθεστώτων Εισαγωγών-Εξαγωγών, Εμπορικής Άμυνας |
| Κορνάρου 1 |
| 105 63 Αθήνα/Athens |
| ΕΛΛΑΔΑ/GREECE |
| Tel. +30 2103286041/43 / 2103286021 |
| Fax +30 2103286094 |

Υπουργείο Ανάπτυξης, Ανταγωνιστικότητας & Ναυτιλίας

Γενική Διεύθυνση Διεθνούς Οικονομικής Πολιτικής

Διεύθυνση Καθεστώτων Εισαγωγών-Εξαγωγών, Εμπορικής Άμυνας

Κορνάρου 1

105 63 Αθήνα/Athens

ΕΛΛΑΔΑ/GREECE

Tel. +30 2103286041/43 / 2103286021

Fax +30 2103286094

| Ministry of Development, Competitiveness and Shipping |
| --- |
| General Directorate for International Economic Policy |
| Directorate of Import-Export Regimes, Trade Defence Instruments |
| Unit A |
| Kornarou 1 |
| 105 63 Athens |
| GREECE |
| Tel. +30 2103286041/43 / 2103286021 |
| Fax +30 2103286094 |

Ministry of Development, Competitiveness and Shipping

General Directorate for International Economic Policy

Directorate of Import-Export Regimes, Trade Defence Instruments

Unit A

Kornarou 1

105 63 Athens

GREECE

Tel. +30 2103286041/43 / 2103286021

Fax +30 2103286094

9.   Spain

| Ministerio de Economía y Competitividad |
| --- |
| Dirección General de Comercio e Inversiones |
| Paseo de la Castellana, 162 |
| 28046 Madrid |
| ESPAÑA |
| Tel. +34 913493817 / 3493874 |
| Fax +34 913493831 |
| E-mail: sgindustrial.sscc@comercio.mineco.es |

Ministerio de Economía y Competitividad

Dirección General de Comercio e Inversiones

Paseo de la Castellana, 162

28046 Madrid

ESPAÑA

Tel. +34 913493817 / 3493874

Fax +34 913493831

E-mail: sgindustrial.sscc@comercio.mineco.es

10.   France

| Ministère du redressement productif |
| --- |
| Direction générale de la compétitivité, de l'industrie et des services |
| Bureau des matérieaux |
| BP 80001 |
| 67 rue Barbès |
| 94201 Ivry-sur-Seine Cedex |
| FRANCE |
| Tel. +33 179843449 |
| E-mail: isabelle.paimblanc@finances.gouv.fr |

Ministère du redressement productif

Direction générale de la compétitivité, de l'industrie et des services

Bureau des matérieaux

BP 80001

67 rue Barbès

94201 Ivry-sur-Seine Cedex

FRANCE

Tel. +33 179843449

E-mail: isabelle.paimblanc@finances.gouv.fr

11.   Italy

| Ministero dello Sviluppo Economico |
| --- |
| Dipartimento per l'impresa e l'internazionalizzazione |
| Direzione Generale per la Politica Commerciale Internazionale |
| Divisione III — Politiche settoriali |
| Viale Boston 25 |
| 00144 Roma RM |
| ITALIA |
| Tel. +39 0659647517 / 59932202 / 59932198 |
| Fax +39 0659932263 / 59932636 |
| E-mail: polcom3@sviluppoeconomico.gov.it |

Ministero dello Sviluppo Economico

Dipartimento per l'impresa e l'internazionalizzazione

Direzione Generale per la Politica Commerciale Internazionale

Divisione III — Politiche settoriali

Viale Boston 25

00144 Roma RM

ITALIA

Tel. +39 0659647517 / 59932202 / 59932198

Fax +39 0659932263 / 59932636

E-mail: polcom3@sviluppoeconomico.gov.it

12.   Cyprus

| Ministry of Commerce, Industry and Tourism |
| --- |
| Trade Department |
| Andrea Araouzou Street 6 |
| 1421 Nicosia |
| CYPRUS |
| Tel. +357 2867100 |
| Fax +357 2375120 |

Ministry of Commerce, Industry and Tourism

Trade Department

Andrea Araouzou Street 6

1421 Nicosia

CYPRUS

Tel. +357 2867100

Fax +357 2375120

13.   Latvia

| Latvijas Republikas Ekonomikas ministrija |
| --- |
| Brīvības iela 55 |
| Rīga, LV-1519 |
| LATVIJA |
| Tel. +371 67013248 |
| Fax +371 67280882 |

Latvijas Republikas Ekonomikas ministrija

Brīvības iela 55

Rīga, LV-1519

LATVIJA

Tel. +371 67013248

Fax +371 67280882

14.   Lithuania

| Lietuvos Respublikos ūkio ministerija |
| --- |
| Gedimino pr. 38/Vasario 16-osios g. 2 |
| LT-01104 Vilnius |
| LIETUVA/LITHUANIA |
| Tel. +370 70664658 / 70664808 |
| Fax +370 70664762 |
| E-mail: vienaslangelis@ukmin.lt |

Lietuvos Respublikos ūkio ministerija

Gedimino pr. 38/Vasario 16-osios g. 2

LT-01104 Vilnius

LIETUVA/LITHUANIA

Tel. +370 70664658 / 70664808

Fax +370 70664762

E-mail: vienaslangelis@ukmin.lt

15.   Luxembourg

| Ministère de l'économie et du commerce exterieur |
| --- |
| Office des licences |
| Boîte postale 113 |
| 2011 Luxembourg |
| LUXEMBOURG |
| Tel. +352 4782371 |
| Fax +352 466138 |

Ministère de l'économie et du commerce exterieur

Office des licences

Boîte postale 113

2011 Luxembourg

LUXEMBOURG

Tel. +352 4782371

Fax +352 466138

16.   Hungary

| Magyar Kereskedelmi Engedélyezési Hivatal |
| --- |
| Budapest |
| Németvölgyi út 37–39. |
| 1124 |
| MAGYARORSZÁG/HUNGARY |
| Tel. +36 14585503 |
| Fax +36 14585814 |
| E-mail: keo@mkeh.gov.hu |

Magyar Kereskedelmi Engedélyezési Hivatal

Budapest

Németvölgyi út 37–39.

1124

MAGYARORSZÁG/HUNGARY

Tel. +36 14585503

Fax +36 14585814

E-mail: keo@mkeh.gov.hu

17.   Malta

| Ministry of Finance, Economy and Investment |
| --- |
| Commerce Department |
| Trade Services Directorate |
| Lascaris |
| Valletta LTV 2000 |
| MALTA |
| Tel. +356 25690202 |
| Fax +356 21237112 |

Ministry of Finance, Economy and Investment

Commerce Department

Trade Services Directorate

Lascaris

Valletta LTV 2000

MALTA

Tel. +356 25690202

Fax +356 21237112

18.   Netherlands

| Belastingdienst/Douane centrale dienst voor in- en uitvoer |
| --- |
| Kempkensberg 12 |
| Postbus 30003 |
| 9700 RD Groningen |
| NEDERLAND |
| Tel. +31 881512122 |
| Fax +31 881513182 |

Belastingdienst/Douane centrale dienst voor in- en uitvoer

Kempkensberg 12

Postbus 30003

9700 RD Groningen

NEDERLAND

Tel. +31 881512122

Fax +31 881513182

19.   Austria

| Bundesministerium für Wirtschaft, Familie und Jugend |
| --- |
| Außenwirtschaftskontrolle |
| Abteilung C2/9 |
| Stubenring 1 |
| 1011 Wien |
| ÖSTERREICH |
| Tel. +43 1711000 |
| Fax +43 1711008386 |

Bundesministerium für Wirtschaft, Familie und Jugend

Außenwirtschaftskontrolle

Abteilung C2/9

Stubenring 1

1011 Wien

ÖSTERREICH

Tel. +43 1711000

Fax +43 1711008386

20.   Poland

| Ministerstwo Gospodarki |
| --- |
| Pl. Trzech Krzyży 3/5 |
| 00-950 Warszawa |
| POLSKA/POLAND |
| Tel. +48 226935553 |
| Fax +48 226934021 |

Ministerstwo Gospodarki

Pl. Trzech Krzyży 3/5

00-950 Warszawa

POLSKA/POLAND

Tel. +48 226935553

Fax +48 226934021

21.   Portugal

| Ministério das Finanças |
| --- |
| Direcção Geral das Alfândegas e dos Impostos Especiais sobre o Consumo |
| Rua Terreiro do Trigo |
| Edifício da Alfândega |
| 1149-060 Lisboa |
| PORTUGAL |
| Tel. +351 1218814263 |
| Fax +351 1218814261 |
| E-mail: dsl@dgaiec.min-financas.pt |

Ministério das Finanças

Direcção Geral das Alfândegas e dos Impostos Especiais sobre o Consumo

Rua Terreiro do Trigo

Edifício da Alfândega

1149-060 Lisboa

PORTUGAL

Tel. +351 1218814263

Fax +351 1218814261

E-mail: dsl@dgaiec.min-financas.pt

22.   Romania

| Ministerul Economiei, Comerțului și Mediului de Afaceri |
| --- |
| Direcția Politici Comerciale |
| Calea Victoriei nr. 152, sector 1 |
| 010096 București |
| ROMÂNIA |
| Tel. +40 213150081 |
| Fax +40 213150454 |
| E-mail: clc@dce.gov.ro |

Ministerul Economiei, Comerțului și Mediului de Afaceri

Direcția Politici Comerciale

Calea Victoriei nr. 152, sector 1

010096 București

ROMÂNIA

Tel. +40 213150081

Fax +40 213150454

E-mail: clc@dce.gov.ro

23.   Slovenia

| Ministrstvo za finance |
| --- |
| Carinska uprava Republike Slovenije |
| Carinski urad Jesenice |
| Center za TARIC in kvote |
| Spodnji Plavž 6 c |
| SI-4270 Jesenice |
| SLOVENIJA |
| Tel. +386 042974470 |
| Fax +386 042974472 |
| E-mail: taric.cuje@gov.si |

Ministrstvo za finance

Carinska uprava Republike Slovenije

Carinski urad Jesenice

Center za TARIC in kvote

Spodnji Plavž 6 c

SI-4270 Jesenice

SLOVENIJA

Tel. +386 042974470

Fax +386 042974472

E-mail: taric.cuje@gov.si

24.   Slovakia

| Ministerstvo hospodárstva SR |
| --- |
| Odbor výkonu obchodných opatrení |
| Mierová 19 |
| 827 15 Bratislava |
| SLOVENSKO/SLOVAKIA |
| Tel. +421 248547019 |
| Fax +421 243423915 |
| E-mail: jan.krocka@mhsr.sk |

Ministerstvo hospodárstva SR

Odbor výkonu obchodných opatrení

Mierová 19

827 15 Bratislava

SLOVENSKO/SLOVAKIA

Tel. +421 248547019

Fax +421 243423915

E-mail: jan.krocka@mhsr.sk

25.   Finland

| Tullihallitus |
| --- |
| PL 512 |
| FI-00101 Helsinki |
| SUOMI/FINLAND |
| Tel. +358 96141 |
| Fax +358 204922852 |

Tullihallitus

PL 512

FI-00101 Helsinki

SUOMI/FINLAND

Tel. +358 96141

Fax +358 204922852

| Tullstyrelsen |
| --- |
| PB 512 |
| FI-00101 Helsingfors |
| SUOMI/FINLAND |
| Fax +358 204922852 |

Tullstyrelsen

PB 512

FI-00101 Helsingfors

SUOMI/FINLAND

Fax +358 204922852

26.   Sweden

| Kommerskollegium |
| --- |
| Box 6803 |
| SE-113 86 Stockholm |
| SVERIGE |
| Tel. +46 86904800 |
| Fax +46 8306759 |
| E-mail: registrator@kommers.se |

Kommerskollegium

Box 6803

SE-113 86 Stockholm

SVERIGE

Tel. +46 86904800

Fax +46 8306759

E-mail: registrator@kommers.se

27.   United Kingdom

| Import Licensing Branch |
| --- |
| Department for Business, Innovation and Skills |
| Queensway House |
| West Precinct |
| Billingham |
| TS23 2NF |
| UNITED KINGDOM |
| E-mail: enquiries.ilb@bis.gsi.gov.uk |

Import Licensing Branch

Department for Business, Innovation and Skills

Queensway House

West Precinct

Billingham

TS23 2NF

UNITED KINGDOM

E-mail: enquiries.ilb@bis.gsi.gov.uk

---

(1)  OJ L 152, 13.6.2012, p. 28.

---